FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

AJANTPHARM Consensus Forecast

No. of reports in last year
2
No. of analysts
1
Average Consensus Forecast
1545
Consensus Potential
-9.02%

AJANTPHARM Price Target Potential

BrokerageTargetPotential
Motilal Oswal1655-1.26%

AJANTPHARM Targets in FrontPage Forums

2 Users have submitted 2 trade ideas of Rs. 337,140 for AJANTPHARM
100% Bullish
0% Bearish
See buy or sell ideas on FrontPage Forums >>

AJANTPHARM Ratings

Long term AJANTPHARM rating by FrontPage users
3/5 (1 Ratings)

2 AJANTPHARM share price target reports by brokerages below. See what is analyst's view on AJANTPHARM share price forecast, rating, estimates, valuation and prediction behind the target. You may use these research report forecasts for long-term to medium term for your investment or trades in 2020.
  1. Home
  2. AJANTPHARM Forum
  3. AJANTPHARM Price Target

AJANTPHARM Share Price Target

AJANTPHARM Share Price Target - Broker Reports - 2020

27-Feb-20
Price @ Call: 1416.72
Target: 1655
BUY
We remain positive on AJP given the improving prospects of a revival in its earnings growth. Furthermore, capex is nearly complete and benefits are likely to accrue from end-FY20. We value AJP at 22x 12M forward earnings (superior profitability and return ratios) and arrive at a price target of INR1,655. Re-iterate Buy.
... Read more
6-Feb-20
Price @ Call: 1198.1
Target: 1435
BUY
We expect 16% earnings CAGR over FY19-22E, led by 14% DF sales, 15% Asia sales and 29% US sales, coupled with improved operating leverage. We also raise the P/E multiple to 21x (from 19x earlier) to factor in the industry outperformance in the branded generics segment. We arrive at TP of INR1,435 (from INR1,124 earlier) on 12M forward earnings basis and reiterate Buy.
... Read more

AJANTPHARM Share Price Target - Broker Reports - 2019

1-Aug-19
Price @ Call: 930.36
Target: 1010
HOLD
Q1 was largely driven by strong growth in Africa and the US business. While the tender business is expected to remain subdued, the branded business (74% of overall revenues) is likely to grow at 10-11%. US business is expected to grow ~30%, albeit on a lower base. Overall, we expect double digit growth in revenues but dent in gross profit, EBITDA and net profit margins due to a change in the product mix (higher US contribution), new plant related expenses and higher depreciation. We arrive at our target price of Rs 1010 based on 20x FY21E EPS of ~| 50.5.
... Read more
2-Feb-19
Price @ Call: 990.03
Target: 1225
BUY
1-Feb-19
Price @ Call: 990.03
Target: 1100
BUY
31-Jan-19
Price @ Call: 1033.62
Target: 1390
BUY

AJANTPHARM Share Price Target - Broker Reports - 2018

1-Aug-18
Price @ Call: 1135.7
Target: 1560
BUY
9-May-18
Price @ Call: 1151.41
Target: 1400
BUY
7-May-18
Price @ Call: 1165.4
Target: 1071
REDUCE
4-May-18
Price @ Call: 1216.45
Target: 1302
HOLD
3-May-18
Price @ Call: 1341.45
Target: 1560
BUY
3-Apr-18
Price @ Call: 1400.63
Target: 1500
BUY
14-Mar-18
Price @ Call: 1370
Target: 1860
BUY
1-Feb-18
Price @ Call: 1406.1
Target: 1520
HOLD
22-Feb-18
Price @ Call: 1357.91
Target: 1840
BUY
25-Jan-18
Price @ Call: 1532.38
Target: 1840
BUY

AJANTPHARM Share Price Target - Broker Reports - 2017

20-Dec-17
Price @ Call: 1465
Target: 1792
BUY
13-Nov-17
Price @ Call: 1204.98
Target: 1520
BUY
7-Nov-17
Price @ Call: 1232.15
Target: 1500
BUY
11-Aug-17
Price @ Call: 1214.6
Target: 1420
BUY
3-May-17
Price @ Call: 1658
Target: 2028
BUY
4-May-17
Price @ Call: 1659
Target: 1880
BUY
11-Apr-17
Price @ Call: 1741
Target: 2028
BUY
20-Mar-17
Price @ Call: 1760
Target: 2028
BUY
25-Jan-17
Price @ Call: 1701
Target: 1960
BUY

AJANTPHARM Share Price Target - Broker Reports - 2016

2-May-16
Price @ Call: 1543
Target: 1780
BUY
27-Oct-16
Price @ Call: 1968
Target: 2220
BUY
2-Sep-16
Price @ Call: 1932.45
Target: 2344
BUY
19-Jul-16
Price @ Call: 1605.15
Target: 1784
BUY
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • AJANTPHARM Share Price Target Today- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 31,757.32
    Upside Target 21,737.63
    Upside Target 11,715.37
    Pivot1,695.68
    Downside Target 11,673.42
    Downside Target 21,653.73
    Downside Target 31,631.47
  • AJANTPHARM Share Price Target weekly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 31,841.6
    Upside Target 21,783.3
    Upside Target 11,738.2
    Pivot1,679.9
    Downside Target 11,634.8
    Downside Target 21,576.5
    Downside Target 31,531.4
  • AJANTPHARM Share Price Target monthly- Technical Pivot Points (Classic)

    keyboard_arrow_down
    Upside Target 32,058.13
    Upside Target 21,853.07
    Upside Target 11,741.13
    Pivot1,536.07
    Downside Target 11,424.13
    Downside Target 21,219.07
    Downside Target 31,107.13
  • AJANTPHARM Share Price Target today- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 31,737.63
    Upside Target 21,721.61
    Upside Target 11,711.71
    Pivot1,695.68
    Downside Target 11,679.66
    Downside Target 21,669.76
    Downside Target 31,653.73
  • AJANTPHARM Share Price Target weekly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 31,783.3
    Upside Target 21,743.8
    Upside Target 11,719.4
    Pivot1,679.9
    Downside Target 11,640.4
    Downside Target 21,616
    Downside Target 31,576.5
  • AJANTPHARM Share Price Target monthly- Technical Pivot Points (Fibonacci)

    keyboard_arrow_down
    Upside Target 31,853.07
    Upside Target 21,731.97
    Upside Target 11,657.16
    Pivot1,536.07
    Downside Target 11,414.97
    Downside Target 21,340.16
    Downside Target 31,219.07
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
PrivacyTerms
FrontPage © 2020